Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

PHASE2RecruitingINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 20, 2026

Study Completion Date

March 20, 2027

Conditions

B-NHLCART Therapy

Interventions

DRUG

zanubrutinib

zanubrutinib 160 mg BID orally

DRUG

CAR-T

CAR-T Cell therapy

RADIATION

Bridging radiotherapy

For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.

DRUG

Tislelizumab

200mg IV Q3-4W

Trial Locations (1)

RECRUITING

Ruijin, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER